COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES